Johnson & Johnson Innovative Medicine in the news

Johnson & Johnson's Innovative Medicine segment anticipates strong Q3 2026 growth driven by oncology, immunology, and neuroscience products, alongside increased contributions from new launches like Inlexzo, Icotyde, and Imaavy, while older drug sales are expected to decline.

Johnson & Johnson Innovative Medicine's Rybrevant offers expanded lung cancer treatment options in Korea, but its high cost and lack of first-line reimbursement significantly limit patient access.

Johnson & Johnson and Myeloma Ireland are collaborating on the 'Miles for Myeloma' challenge to raise awareness and support for people with multiple myeloma.

Eli Lilly's robust growth in GLP-1 therapies contrasts with Johnson & Johnson's diversified business model, with both companies projecting strong future growth despite challenges.

Johnson & Johnson navigates significant headwinds including patent expirations for key drugs, weakness in its MedTech division, and ongoing talc litigation, yet remains confident in its long-term growth and revenue targets.

María Pobre has been appointed General Manager for Johnson & Johnson's Innovative Medicine commercial operations in Ireland.

Shockwave Medical, a Johnson & Johnson subsidiary, will rebrand as Johnson & Johnson MedTech on October 1, focusing on circulatory restoration solutions.

Johnson & Johnson (JNJ) has shown strong stock performance, outperforming the Consumer Staples sector due to robust pharmaceutical growth and a resilient MedTech business, with positive Q2 FY2026 earnings and an increased outlook.

Johnson & Johnson, a multinational healthcare company, develops new treatments and medical technologies in pharmaceuticals and devices.

Zacks Industry Outlook highlights Eli Lilly, Johnson & Johnson, and Bayer as large-cap pharmaceutical stocks to watch amid a strong industry recovery, driven by innovation, M&A, and new drug successes, despite challenges like patent expirations and pricing pressures.

Johnson & Johnson's stock is performing strongly, driven by its Innovative Medicines segment and new product launches, despite patent expirations and ongoing talc litigation.

Tom Cavanaugh will become Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, succeeding Jennifer Taubert on September 1, 2026.

Johnson & Johnson appointed Tom Cavanaugh to succeed Jennifer Taubert as EVP, Worldwide Chairman, Innovative Medicine, effective September 2026, signaling a leadership transition in its pharmaceutical segment.

Jennifer Taubert retired as EVP and Worldwide Chairman of Johnson & Johnson's Innovative Medicine, succeeded by Tom Cavanaugh, signaling continuity in the company's core growth strategy amidst ongoing product and legal challenges.

Johnson & Johnson's Q2 results exceeded expectations, driven by strong performance in Innovative Medicine, which compensated for weaker MedTech sales, leading to an increased full-year outlook.

Johnson & Johnson's Innovative Medicine division sees a leadership transition as Jennifer Taubert retires and Tom Cavanaugh steps in, maintaining focus on oncology growth and existing challenges.

Johnson & Johnson is changing its leadership in the Innovative Medicine segment with Tom Cavanaugh succeeding Jennifer Taubert in 2026.

Johnson & Johnson appointed Tom Cavanaugh as Executive Vice President, Worldwide Chairman Innovative Medicine, succeeding the retiring Jennifer Taubert.

Tom Cavanaugh will succeed Jennifer Taubert as Head of Johnson & Johnson's Innovative Medicine division on September 1, 2026, bringing extensive biopharmaceutical experience to continue the division's growth.

Tom Cavanaugh will lead Johnson & Johnson's Innovative Medicine division, facing the challenge of launching new drug Icotyde while managing the decline of Stelara amid biosimilar competition.